Zentalis Pharmaceuticals

Zentalis Pharmaceuticals(ZNTL)

SAN DIEGO, CA
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Small Molecules

Zentalis Pharmaceuticals is a life sciences company focused on Small Molecules.

Neurology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT04516447A Study of ZN-c3 in Patients With Ovarian Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04854174A Food Effect Study of ZN-d5 in Healthy Female Volunteers
Phase 1
ZN-c3
Tumors
Phase 1
Clinical Trials (1)
NCT05431582Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT04158336A Study of ZN-c3 in Participants With Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT04500587Phase 1 First in Human Study of ZN-d5 as a Single Agent
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04833582A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05199337Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05682170Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05198804A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Phase 1/2
Azenosertib
Breast Cancer
Phase 1/2
Phase 2
Clinical Trials (1)
NCT04814108A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Phase 2
Phase 2
Clinical Trials (1)
NCT06369155Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Phase 2
Phase 2
Clinical Trials (1)
NCT06015659ZN-c3 + Gemcitabine in Pancreatic Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT05128825A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 13 clinical trials
SEC Filings: 2 available

Financials (FY2024)

Revenue
$0
R&D Spend
$173M2%
Net Income
-$237M
Cash
$43M
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles